Clinical Trials Logo

Clinical Trial Summary

This is an open-label, single-arm study of sofosbuvir (GS-7977) and ribavirin (RBV) in adults who have had a liver transplant which has become re-infected with hepatitis C. The treatment period is 24 weeks with up to 48 weeks of follow up. The total time in this study will last up to 72 weeks not including the screening visit.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01687270
Study type Interventional
Source Gilead Sciences
Contact
Status Completed
Phase Phase 2
Start date November 2012
Completion date August 2014

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05063071 - Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant Phase 4
Active, not recruiting NCT03386305 - Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant Phase 2/Phase 3
Recruiting NCT06304467 - CM for Patients With ALD After Liver Transplant N/A